{
  "denotations": [
    {
      "id": "T1",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 4,
        "end": 19
      }
    },
    {
      "id": "T2",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 22,
        "end": 24
      }
    },
    {
      "id": "T3",
      "obj": "Chemical",
      "span": {
        "begin": 39,
        "end": 47
      }
    },
    {
      "id": "T4",
      "obj": "Disease",
      "span": {
        "begin": 80,
        "end": 92
      }
    },
    {
      "id": "T5",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 142,
        "end": 147
      }
    },
    {
      "id": "T6",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 150,
        "end": 155
      }
    },
    {
      "id": "T7",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 160,
        "end": 166
      }
    },
    {
      "id": "T8",
      "obj": "Chemical",
      "span": {
        "begin": 4,
        "end": 36
      }
    },
    {
      "id": "T9",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 132,
        "end": 139
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "19182535_2",
  "text": "The tyrosine kinase ( TK ) inhibitor , imatinib , has revolutionized therapy of malignancies that are addicted to one of its target kinases , c-abl , c-kit and PDGF-R ."
}
